Anti-tumor activity and repression of MYC by BET inhibitors have been shown in various malignancies including multiple myeloma (MM), Burkitt’s lymphoma, and acute myelogenous leukemia (AML) [32, 33, 56, 57]. This evidence concerns the gene MYC and Burkitt lymphoma.